| 6.293 0.143 (2.33%) | 05-23 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term | |
|||
| Targets | 6-month : | 8.16 |
1-year : | 9.53 |
| Resists | First : | 6.98 |
Second : | 8.16 |
| Pivot price | 6.41  |
|||
| Supports | First : | 6.06 |
Second : | 5.5 |
| MAs | MA(5) : | 6.25 |
MA(20) : | 6.42 |
| MA(100) : | 5.89 |
MA(250) : | 5.68 |
|
| MACD | MACD : | 0 |
Signal : | 0 |
| %K %D | K(14,3) : | 11.7 |
D(3) : | 9.8 |
| RSI | RSI(14): 50 |
|||
| 52-week | High : | 7.38 | Low : | 0 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ BHST ] has closed above bottom band by 30.3%. Bollinger Bands are 49.4% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 8 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 6.39 - 6.42 | 6.42 - 6.45 |
| Low: | 6.05 - 6.08 | 6.08 - 6.11 |
| Close: | 6.23 - 6.29 | 6.29 - 6.35 |
BioHarvest Sciences Inc. operates as a biotechnology company. The company operates through Nutraceuticals and Pharmaceuticals segments. It develops botanical synthesis platform technology to grow the ingredients in any plant enzymes or cells. The company is leveraging its botanical synthesis technology to develop science-based and clinically proven therapeutic solutions in nutraceuticals and pharmaceuticals verticals. It also operates as a contract development and manufacturing operation services. In addition, the company offers wellness products. Further, it offers VINIA, a red grape cell dietary supplement containing the matrix of polyphenols contained in red grapes. The company operates in Israel and the United States. BioHarvest Sciences Inc. is based in Vancouver, Canada.
Wed, 21 May 2025
BioHarvest Secures New CDMO Contract to Develop Plant-based Fragrance Compound - marketscreener.com
Mon, 19 May 2025
BioHarvest Sciences: Investors Remain Unconvinced Post Q1 Earnings Release - Seeking Alpha
Thu, 15 May 2025
Transcript : BioHarvest Sciences Inc., Q1 2025 Earnings Call, May 15, 2025 - marketscreener.com
Thu, 15 May 2025
BioHarvest Sciences Achieves 47% Revenue Growth in Q1 2025 - TipRanks
Thu, 01 May 2025
BioHarvest Sciences to Host First Quarter 2025 Earnings Call on May 15 at 4:30 p.m. Eastern Time - Newsfile
Thu, 01 May 2025
BioHarvest Sciences to Announce Q1 2025 Financial Results - TipRanks
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Basic Materials
|
|
|
Industry:
Agricultural - Commodities/Milling
|
|
| Shares Out | 17 (M) |
| Shares Float | 13 (M) |
| Held by Insiders | 25.9 (%) |
| Held by Institutions | 0.7 (%) |
| Shares Short | 3 (K) |
| Shares Short P.Month | 7 (K) |
| EPS | -0.81 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.07 |
| Profit Margin | -51.3 % |
| Operating Margin | -23.2 % |
| Return on Assets (ttm) | -21.9 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | 61 % |
| Gross Profit (p.s.) | 0.8 |
| Sales Per Share | 1.45 |
| EBITDA (p.s.) | -0.38 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -7 (M) |
| Levered Free Cash Flow | -4 (M) |
| PE Ratio | -7.87 |
| PEG Ratio | 0 |
| Price to Book value | 78.66 |
| Price to Sales | 4.32 |
| Price to Cash Flow | -16.33 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|